Authors

1. Aschenbrenner, Diane S. MS, RN

Abstract

* A new treatment is now available for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer. Palbociclib (Ibrance) inhibits cyclin-dependent kinases 4 and 6.